Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery

References

• Elsayed I, AbouGhaly MH. Inhalable nanocomposite microparticles: preparation, characterization and factors affecting formulation. Expert Opin Drug Deliv. 2016;13(2):207–222. doi:10.1517/17425247.2016.110222426512950
   PubMed Web of Science ®Google Scholar
• Muralidharan P, Malapit M, Mallory E, Hayes D Jr., Mansour HM. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine. 2015;11(5):1189–1199. doi:10.1016/j.nano.2015.01.00725659645
   PubMed Web of Science ®Google Scholar
• Manca ML, Valenti D, Sales OD, Nacher A, Fadda AM, Manconi M. Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin. Int J Pharm. 2014;472(1–2):102–109. doi:10.1016/j.ijpharm.2014.06.00924928129
   PubMedGoogle Scholar
• Sosnik A, Carcaboso ÁM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev. 2010;62(4–5):547–559. doi:10.1016/j.addr.2009.11.02319914315
   PubMed Web of Science ®Google Scholar
• Sagalowicz L. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO; 2012.
   Google Scholar
• Padayatchi N, Friedland G. Decentralised management of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis. 2008;12(8):978–980.18647461
   PubMed Web of Science ®Google Scholar
• Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26(11):2401–2416. doi:10.1007/s11095-009-9957-420183916
   PubMed Web of Science ®Google Scholar
• Shegokar R, Al Shaal L, Mitri K. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci. 2011;14(1):100–116.21501557
   PubMed Web of Science ®Google Scholar
• Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–629. doi:10.1016/S1473-3099(10)70139-020797644
   PubMed Web of Science ®Google Scholar
• Mehanna MM, Mohyeldin SM, Elgindy NA. Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J Control Release. 2014;187:183–197. doi:10.1016/j.jconrel.2014.05.03824878180
   PubMed Web of Science ®Google Scholar
• Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–570. doi:10.1016/j.tibtech.2007.09.00517997181
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother. 2005;55(4):430–435. doi:10.1093/jac/dki02715761077
   PubMed Web of Science ®Google Scholar
• Malamatari M, Somavarapu S, Bloxham M, Buckton G. Nanoparticle agglomerates of indomethacin: the role of poloxamers and matrix former on their dissolution and aerosolisation efficiency. Int J Pharm. 2015;495(1):516–526. doi:10.1016/j.ijpharm.2015.09.01326364709
   PubMedGoogle Scholar
• Watts AB, Williams RO III. Nanoparticles for Pulmonary Delivery. Controlled Pulmonary Drug Delivery. Springer; 2011:335–366.
   Google Scholar
• Yang Y, Cheow WS, Hadinoto K. Dry powder inhaler formulation of lipid-polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles. Int J Pharm. 2012;434(1–2):49–58. doi:10.1016/j.ijpharm.2012.05.03622634138
   PubMedGoogle Scholar
• Tomoda K, Ohkoshi T, Kawai Y, Nishiwaki M, Nakajima T, Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf B Biointerfaces. 2008;61(2):138–144. doi:10.1016/j.colsurfb.2007.07.01617890065
   PubMed Web of Science ®Google Scholar
• Tomoda K, Ohkoshi T, Hirota K, et al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces. 2009;71(2):177–182. doi:10.1016/j.colsurfb.2009.02.00119264458
   PubMed Web of Science ®Google Scholar
• Tomoda K, Ohkoshi T, Nakajima T, Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B Biointerfaces. 2008;64(1):70–76. doi:10.1016/j.colsurfb.2008.01.01618343097
   PubMed Web of Science ®Google Scholar
• Yang M, Yamamoto H, Kurashima H, et al. Design and evaluation of poly(DL-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. Eur J Pharm Sci. 2012;46(5):374–380. doi:10.1016/j.ejps.2012.02.02422414702
   PubMed Web of Science ®Google Scholar
• Mohyeldin SM, Mehanna MM, Elgindy NA. The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity. Int J Nanomed. 2016;11:2209–2222.
   PubMed Web of Science ®Google Scholar
• Singh C, Koduri LVSK, Singh A, Suresh S. Novel potential for optimization of antitubercular therapy: pulmonary delivery of rifampicin lipospheres. Asian J Pharm Sci. 2015;10(6):549–562. doi:10.1016/j.ajps.2015.08.003
   Web of Science ®Google Scholar
• The United States Pharmacopoeia. Thirty Eight Ed: The National Formulary, the Official Compendia of Standards.Washington, DC: United States Pharmacopoeial Convention, Inc.. ; 2015:1327–1329.
   Google Scholar
• El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009;26(7):1752–1763. doi:10.1007/s11095-009-9886-219415471
   PubMed Web of Science ®Google Scholar
• Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27(1):48–49. doi:10.1111/j.2042-7158.1975.tb09378.x235616
   PubMed Web of Science ®Google Scholar
• Duret C, Wauthoz N, Sebti T, Vanderbist F, Amighi K. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int J Nanomedicine. 2012;7:5475–5489. doi:10.2147/IJN.S3409123093903
   PubMed Web of Science ®Google Scholar
• Ishak RA, Osman R. Lecithin/TPGS-based spray-dried self-microemulsifying drug delivery systems: in vitro pulmonary deposition and cytotoxicity. Int J Pharm. 2015;485(1–2):249–260. doi:10.1016/j.ijpharm.2015.03.01925772421
   PubMedGoogle Scholar
• Ungaro F, d’Angelo I, Coletta C, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release. 2012;157(1):149–159. doi:10.1016/j.jconrel.2011.08.01021864595
   PubMed Web of Science ®Google Scholar
• Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60(8):863–875. doi:10.1016/j.addr.2007.11.00618308418
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1–2):1–19. doi:10.1016/j.ijpharm.2010.03.01720223286
   PubMed Web of Science ®Google Scholar
• Al-Qadi S, Grenha A, Carrion-Recio D, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release. 2012;157(3):383–390. doi:10.1016/j.jconrel.2011.08.00821864592
   PubMed Web of Science ®Google Scholar
• Grenha A, Remunan-Lopez C, Carvalho EL, Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm. 2008;69(1):83–93. doi:10.1016/j.ejpb.2007.10.01718166446
   PubMed Web of Science ®Google Scholar
• Sinsuebpol C, Chatchawalsaisin J, Kulvanich P. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther. 2013;7:861–873. doi:10.2147/DDDT.S47681
   PubMed Web of Science ®Google Scholar
• Gradon L, Sosnowski TR. Formation of particles for dry powder inhalers. Adv Powder Technol. 2014;25(1):43–55. doi:10.1016/j.apt.2013.09.012
   Web of Science ®Google Scholar
• Li X, Vogt FG, Hayes D Jr., Mansour HM. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. Eur J Pharm Sci. 2014;52:191–205. doi:10.1016/j.ejps.2013.10.01624215736
   PubMed Web of Science ®Google Scholar
• Osman R, Kan PL, Awad G, Mortada N, El-Shamy AE, Alpar O. Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity. Int J Pharm. 2013;449(1–2):44–58. doi:10.1016/j.ijpharm.2013.04.00923587967
   PubMed Web of Science ®Google Scholar
• Kumar S, Gokhale R, Burgess DJ. Sugars as bulking agents to prevent nano-crystal aggregation during spray or freeze-drying. Int J Pharm. 2014;471(1–2):303–311. doi:10.1016/j.ijpharm.2014.05.06024939612
   PubMedGoogle Scholar
• Mehanna MM, Alwattar JK, Elmaradny HA. Optimization, physicochemical characterization and in vivo assessment of spray dried emulsion: A step toward bioavailability augmentation and gastric toxicity minimization. Int J Pharm. 2015;496(2):766–779. doi:10.1016/j.ijpharm.2015.11.00926561726
   PubMedGoogle Scholar
• Kuehl PJ, Cherrington A, Dobry DE, et al. Biologic comparison of inhaled insulin formulations: exubera and novel spray-dried engineered particles of dextran-10. AAPS Pharm SciTech. 2014;15(6):1545–1550. doi:10.1208/s12249-014-0181-0
   PubMed Web of Science ®Google Scholar
• Moghaddam PH, Ramezani V, Esfandi E, et al. Development of a nano–micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol. 2013;239:478–483. doi:10.1016/j.powtec.2013.02.025
   Web of Science ®Google Scholar
• Osman R, Al Jamal KT, Kan PL, et al. Inhalable DNase I microparticles engineered with biologically active excipients. Pulm Pharmacol Ther. 2013;26(6):700–709. doi:10.1016/j.pupt.2013.07.01023933140
   PubMedGoogle Scholar
• Pomázi A, Buttini F, Ambrus R, Colombo P, Szabó-Révész P. Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam. Eur Polym J. 2013;49(9):2518–2527. doi:10.1016/j.eurpolymj.2013.03.017
   Web of Science ®Google Scholar
• Cruz L, Fattal E, Tasso L, et al. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release. 2011;152(3):370–375. doi:10.1016/j.jconrel.2011.02.03021396412
   PubMed Web of Science ®Google Scholar
• Al-Hallak MH, Sarfraz MK, Azarmi S, Roa WH, Finlay WH, Lobenberg R. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther Deliv. 2011;2(10):1313–1324.22826885
   PubMedGoogle Scholar
• Gervelas C, Serandour AL, Geiger S, et al. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium. J Control Release. 2007;118(1):78–86. doi:10.1016/j.jconrel.2006.11.02717241685
   PubMed Web of Science ®Google Scholar
• Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005;25(4–5):427–437. doi:10.1016/j.ejps.2005.04.00915893461
   PubMed Web of Science ®Google Scholar
• Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS Pharm SciTech. 2002;3(4):7–16. doi:10.1208/pt030428
   PubMedGoogle Scholar
• Pourshahab PS, Gilani K, Moazeni E, Eslahi H, Fazeli MR, Jamalifar H. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul. 2011;28(7):605–613. doi:10.3109/02652048.2011.59943721793647
   PubMed Web of Science ®Google Scholar
• Chew NY, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res. 2001;18(11):1570–1577. doi:10.1023/a:101308253139411758765
   PubMed Web of Science ®Google Scholar
• Yue PF, Li Y, Wan J, Yang M, Zhu WF, Wang CH. Study on formability of solid nanosuspensions during nanodispersion and solidification: I. Novel role of stabilizer/drug property. Int J Pharm. 2013;454(1):269–277. doi:10.1016/j.ijpharm.2013.06.05023830942
   PubMed Web of Science ®Google Scholar
• Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm. 2012;424(1–2):98–106. doi:10.1016/j.ijpharm.2011.12.04522226876
   PubMedGoogle Scholar
• Crowder T, Hickey A. Powder specific active dispersion for generation of pharmaceutical aerosols. Int J Pharm. 2006;327(1–2):65–72. doi:10.1016/j.ijpharm.2006.07.05016930884
   PubMedGoogle Scholar
• Nasr M, Awad GA, Mansour S, Taha I, Al Shamy A, Mortada ND. Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting. Eur J Pharm Biopharm. 2011;79(3):601–611. doi:10.1016/j.ejpb.2011.07.01021827854
   PubMed Web of Science ®Google Scholar
• Yang JJ, Liu CY, Quan LH, Liao YH. Preparation and in vitro aerosol performance of spray-dried Shuang-Huang-Lian corrugated particles in carrier-based dry powder inhalers. AAPS Pharm SciTech. 2012;13(3):816–825. doi:10.1208/s12249-012-9806-3
   PubMed Web of Science ®Google Scholar
• Chew NY, Tang P, Chan HK, Raper JA. How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharm Res. 2005;22(1):148–152. doi:10.1007/s11095-004-9020-415771241
   PubMed Web of Science ®Google Scholar
• El-Gendy N, Aillon KL, Berkland C. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int J Pharm. 2010;391(1–2):305–312. doi:10.1016/j.ijpharm.2010.03.00920214960
   PubMedGoogle Scholar
• Peters K, Leitzke S, Diederichs JE, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;45(1):77–83. doi:10.1093/jac/45.1.7710629016
   PubMed Web of Science ®Google Scholar
• Zhao H, Kang XL, Chen XL, et al. Antibacterial activities of amorphous cefuroxime axetil ultrafine particles prepared by high gravity antisolvent precipitation (HGAP). Pharm Dev Technol. 2009;14(5):485–491. doi:10.1080/1083745090276299119743947
   PubMed Web of Science ®Google Scholar
• Esfandi E, Ramezani V, Vatanara A, Rouholamini Najafabadi A, Hadipour Moghaddam SP. Clarithromycin dissolution enhancement by preparation of aqueous nanosuspensions using sonoprecipitation technique. Iran J Pharm Res. 2014;13(3):809–818.25276181
   PubMed Web of Science ®Google Scholar
• Ambhore NP, Dandagi PM, Gadad AP. Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery. Drug Deliv Transl Res. 2016;6(1):48–56. doi:10.1007/s13346-015-0262-y26545605
   PubMedGoogle Scholar
• Galli C. Experimental determination of the diffusion boundary layer width of micron and submicron particles. Int J Pharm. 2006;313(1–2):114–122. doi:10.1016/j.ijpharm.2006.01.03016529883
   PubMedGoogle Scholar
• Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm. 1998;160(2):229–237. doi:10.1016/S0378-5173(97)00311-6
   Web of Science ®Google Scholar
• Kumar S, Gokhale R, Burgess DJ. Quality by Design approach to spray drying processing of crystalline nanosuspensions. Int J Pharm. 2014;464(1–2):4234–4242.
   Google Scholar
• Duret C, Wauthoz N, Sebti T, Vanderbist F, Amighi K. New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis. Pharm Res. 2012;29(10):2845–2859. doi:10.1007/s11095-012-0779-422644590
   PubMedGoogle Scholar
• Yamasaki K, Kwok PC, Fukushige K, Prud’homme RK, Chan HK. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm. 2011;420(1):34–42. doi:10.1016/j.ijpharm.2011.08.01021864662
   PubMedGoogle Scholar
• Valizadeh H, Nokhodchi A, Qarakhani N, et al. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev Ind Pharm. 2004;30(3):303–317. doi:10.1081/ddc-12003042615109030
   PubMed Web of Science ®Google Scholar
• Kho K, Hadinoto K. Optimizing aerosolization efficiency of dry-powder aggregates of thermally-sensitive polymeric nanoparticles produced by spray-freeze-drying. Powder Technol. 2011;214(1):169–176. doi:10.1016/j.powtec.2011.08.010
   Web of Science ®Google Scholar
• Weiler C, Egen M, Trunk M, Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99(1):303–316. doi:10.1002/jps.2184919533606
   PubMedGoogle Scholar
• Yu H, Teo J, Chew JW, Hadinoto K. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: spray drying versus spray freeze drying preparation. Int J Pharm. 2016;499(1–2):38–46. doi:10.1016/j.ijpharm.2015.12.07226757148
   PubMedGoogle Scholar
• Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci. 2004;22(2–3):127–144. doi:10.1016/j.ejps.2004.02.01115158898
   PubMed Web of Science ®Google Scholar
• Krishnaiah D, Sarbatly R, Nithyanandam R. Microencapsulation of Morinda citrifolia L. extract by spray-drying. Chem Eng Res Des. 2012;90(5):622–632. doi:10.1016/j.cherd.2011.09.003
   Web of Science ®Google Scholar
• De Souza VB, Thomazini M, Balieiro J, Fávaro-Trindade CS. Effect of spray drying on the physicochemical properties and color stability of the powdered pigment obtained from vinification byproducts of the Bordo grape (Vitis labrusca). Food Bioprod Process. 2015;93:39–50. doi:10.1016/j.fbp.2013.11.001
   Web of Science ®Google Scholar
• Bruni G, Berbenni V, Milanese C, et al. Physico-chemical characterization of anhydrous D-mannitol. J Therm Anal Calorim. 2009;95(3):871–876. doi:10.1007/s10973-008-9384-5
   Web of Science ®Google Scholar
• Kaewjan K, Srichana T. Nano spray-dried pyrazinamide-l-leucine dry powders, physical properties and feasibility used as dry powder aerosols. Pharm Dev Technol. 2016;21(1):68–75. doi:10.3109/10837450.2014.97137325331092
   PubMed Web of Science ®Google Scholar
• Chuan J, Li Y, Yang L, et al. Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles. J Nanopart Res. 2013;15(5):1–9. doi:10.1007/s11051-013-1634-1
   Web of Science ®Google Scholar
• Dong S, HiraniI AA, Colacino KYR, LEE YW, Roman M. Cytotoxicity and cellular uptake of cellulose nanocrystals. Nano Life. 2012;02(03):1241006–1241015.
   Google Scholar
• Zhang H, Hollis CP, Zhang Q, Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm. 2011;415(1–2):293–300. doi:10.1016/j.ijpharm.2011.05.07521679755
   PubMedGoogle Scholar
• Mahmoud KA, Mena JA, Male KB, Hrapovic S, Kamen A, Luong JH. Effect of surface charge on the cellular uptake and cytotoxicity of fluorescent labeled cellulose nanocrystals. ACS Appl Mater Interfaces. 2010;2(10):2924–2932. doi:10.1021/am100622220919683
   PubMed Web of Science ®Google Scholar